Alcohol Use Disorder (AUD)
105
37
42
28
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
11 trials with published results (10%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
4.8%
5 terminated out of 105 trials
84.8%
-1.7% vs benchmark
3%
3 trials in Phase 3/4
39%
11 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 28 completed trials
Clinical Trials (105)
Repetitive Transcranial Magnetic Stimulation for Alcohol Use Disorder
Alpha Down EEG Neurofeedback for Alcohol Use Disorder: Feasibility Trial
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
TRIS: Contingency Management App for Alcohol Use Disorder
Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Brain Inflammation and Function in Alcoholism
Feasibility and Effects of Activity Trackers Among Alcohol Users Receiving In-patient Treatment for Alcohol Use Disorder
Acceptability and Feasibility Study of Non-alcoholic Beverages
Body-Focused Mindfulness as an Add-on Intervention in Inpatient Alcohol Use Disorder Treatment (MBI-AUD-PL)
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Prevention of Relapse Through Cognitive Cycling in Patients With Alcohol Use Disorder Following Alcohol Withdrawal
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
Study of Tirzepatide for Recovery and Alcohol Use Management
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
Optimizing Smart Technology for Addiction Recovery
Suvorexant for Treatment of AUD and PTSD
Deaf CBT-TS to Reduce Suicide Risk
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms